share_log

宜明昂科-B(01541):IMM0306获国家药监局批准进行狼疮性肾炎治疗的II期临床试验

I-Mab BioPharma-B (01541): IMM0306 has been approved by the National Medical Products Administration for phase II clinical trials for the treatment of lupus nephritis.

Zhitong Finance ·  14:42

Yiming Biotech-B (01541) announced that the group has been approved by the National Medical Products Administration of the People's Republic of China to proceed...

According to智通财经APP, Yiming Biotech-B (01541) announced that the group has been approved by the National Medical Products Administration of the People's Republic of China to conduct a Phase II clinical trial for IMM0306 (an innovative drug bispecific antibody targeting CD47xCD20) for the treatment of lupus nephritis (LN).

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment